This website is intended for healthcare professionals only.

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Share this article

Follow by Email
Facebook
Twitter

Addition of rituximab improves survival in children with B-cell lymphomas


16 June, 2020  

Addition of rituximab to standard chemotherapy for children with high grade, B-cell cancer prolongs event-free survival and overall survival according to the results of a new study.

Researchers from the European intergroup for childhood non-Hodgkin lymphoma and oncology group, recently published data from a Phase III, international, randomised clinical trial in patients under 18 years of age who had a high-risk, mature B-cell lymphoma (stage III) or acute leukaemia.

The trial compared the addition of six doses of rituximab to standard lymphoma malins B (LMB) chemotherapy against LMB therapy alone in 328 patients.

The primary endpoint was event-free survival which was defined in several ways including relapse, progressive disease, second cancer or death from any cause. After a median follow-up of 39.9 months, there were ten events in the rituximab group compared with 28 in the LMB group and the event-free survival rate was 93.9% in patients given rituximab compared to 82.3% in the LMB group. In total, eight patients treated with rituximab died compared with 20 in the LMB group.

However, although more effective, treatment with rituximab resulted in 37.7% of patients experiencing serious adverse effects, mainly febrile neutropenia, compared with 32.7% in the LMB group.

Reference
Minard-Colin V et al. Rituximab for high-risk, mature B-cell non-Hodgkin’s lymphoma in children. N Engl J Med 2020;382:2207-19.